de Roij van Zuijdewijn Camiel, van Dorp Wim, Florquin Sandrine, Roelofs Joris, Verburgh Kees
Department of Internal Medicine, Spaarne Gasthuis, Haarlem/Hoofddorp, the Netherlands.
Department of Nephrology & Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Br J Clin Pharmacol. 2021 Sep;87(9):3485-3491. doi: 10.1111/bcp.14780. Epub 2021 Mar 4.
From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis. Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs.
从大鼠研究、人类病例报告和队列研究来看,双膦酸盐似乎会损害肾功能。然而,在严格审视文献时,唑来膦酸和帕米膦酸比其他双膦酸盐更常导致肾功能恶化。当发生双膦酸盐肾病时,唑来膦酸更常诱发肾小管毒性,而帕米膦酸通常诱发局灶节段性肾小球硬化。因此,尽管双膦酸盐在预防骨转移患者的并发症方面非常有效,在预防骨质疏松症患者骨折方面也非常有效,但在开始使用这些药物后,应密切监测肾功能。